Avid Bioservices, Inc. reiterating revenue guidance for the fiscal year 2022. The company is reiterating revenue guidance for fiscal 2022 of $115 million to $117 million, a 20% to 22% increase over fiscal 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.54 USD | +10.72% |
|
+6.42% | +16.00% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.00% | 432M | |
+2.22% | 93.53B | |
-1.32% | 38.27B | |
-13.44% | 32.84B | |
+76.30% | 27.83B | |
-13.11% | 16.08B | |
+0.68% | 14.02B | |
-12.06% | 11.47B | |
+185.28% | 9.92B | |
-53.00% | 9.42B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022